Loading
Up to half of women with metastatic HER2-positive breast cancer develop brain metastases, because antibodies control the body but historically not the brain.
Incidence 30-50% in metastatic HER2+ disease. Local therapy (radiosurgery, surgery, whole-brain RT) was the mainstay; tucatinib (HER2CLIMB: CNS-PFS HR 0.32) and T-DXd (DESTINY-Breast12: intracranial ORR 71.7%) now provide systemic control, allowing deferral of radiation in selected patients. Neratinib and pyrotinib have modest CNS activity.
Showing the molecule this term concerns: Tucatinib.
Shares Systemic-first management of HER2-positive brain metastases, HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib.
Shares Tucatinib, The brain: barrier and sanctuary, MRI, Trastuzumab deruxtecan.
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib.
Shares Systemic-first management of HER2-positive brain metastases, HER2-positive breast cancer with brain metastases, Trastuzumab deruxtecan.
Shares Deliver CAR-T cells straight into the fluid around the brain, Use the brain's own transport door to carry antibody drugs across, HER2-positive breast cancer.
Shares Use the brain's own transport door to carry antibody drugs across, Organ tropism: seed and soil, The blood-brain barrier & brain metastasis, Brain metastases (secondary brain tumours).
Shares HER2-positive breast cancer with brain metastases, Tucatinib, HER2-positive breast cancer.
Shares HER2CLIMB, Tucatinib, HER2-positive breast cancer.